Keros Therapeutics, Inc. (KROS) Tops Q3 EPS by 2c

Keros Therapeutics, Inc. (NASDAQ: KROS) reported Q3 EPS of ($1.33), $0.02 better than the analyst estimate of ($1.35). Revenue for the quarter came in at $8 thousand.

For earnings history and earnings-related data on Keros Therapeutics, Inc. (KROS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c